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Ossifying fibromaa b s t r a c t
Background: Fibrous dysplasia (FD) and ossifying fibroma (OF) are fibro-osseous lesions (FOLs) having
several overlaps that may make final diagnosis difficult by hematoxylin and eosin (H/E) alone.
Aim: This study seeks to detect any association between Azan and Toluidine blue staining as compared
with osteocalcin in FD and OF diagnosis.
Methods: Forty formalin fixed paraffin embedded (FFPE) blocks of FD and OF were prepared for Azan,
Toluidine blue and osteocalcin staining. Brown staining of calcified structures was considered as positive
for osteocalcin. Scoring for Azan and Toluidine blue was evaluated based on intensity and localization.
Level of agreement of original and revised diagnosis was determined.
Results: Six (40%) of 15 FD were corroborated by osteocalcin. Eight cases initially diagnosed as OF were
revised to FD. There were 25 OF according to H/E, and 17 (68%) were validated by osteocalcin. Measure of
agreement between histology and immunohistochemistry was 0.081; p = .608. Eleven (42.3%) OF
expressed strong toluidine blue staining of the intervening fibrous connective tissue stroma while only
2 (14.2%) FD showed similar staining, this difference was statistically significant [p = .001].
Conclusions: Histomorphometric analysis with Toluidine blue may reduce diagnostic errors of OF and FD.
 2018 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Fibrous dysplasia (FD) and ossifying fibroma (OF) are
fibro-osseous lesions (FOLs). FOLs are diverse jaw disorders charac-
terized by the replacement of normal bone with benign fibrous
connective tissue matrix and a secondary attempt at new bone for-
mation.1–3 Although there are some differences in the biologicbehavior, clinical presentation and radiography of these two
lesions, there are several overlaps that may make final diagnosis
difficult.4 The histology of the two lesions, again, is so similar, that
it is virtually impossible to make a diagnosis of either one of them
based on histology alone. The basis for final diagnosis and clear
objectivity is therefore called into question. So, with overlapping
clinical presentation and indistinct histology, reliable diagnosis
can only be reached by further investigations.
Establishing related genetic disorders in these two conditions
have served to separate them. Polymerase Chain Reaction analysis
for mutations at Arg-201 codon of the alpha subunit of the trans-
membrane stimulatory G protein gene (GNAS-1) has been shown
to be a marker for jaw FD.5 Another report found a mutation of
the tumor suppressor gene HRPT2 in OF and suggested that OF
was due to haploinsufficiency of the HRPT2 gene.6 Immunohisto-
chemical marking for several bone matrix proteins have shown
no significant differences between FD and OF except for osteocal-
cin, which has strong expression in the calcified regions of FD,
but is weak in OF lesions.5 Osteocalcin is the most abundant
694 S.E. Udeabor et al. / Alexandria Journal of Medicine 54 (2018) 693–697non-collagenous protein distributed in normal bone and is a nega-
tive regulator of bone formation. The abundance of osteocalcin in
FD contrasted with OF implies that the calcified material in FD is
comparable to normal bone than that in OF.7
Distinguishing between FD and OF using either the genetic or
immunohistochemical tests in each case of a FOL may not be fea-
sible in all cases for all laboratories due to overhead costs and or
patients inability to afford such tests. Also the results of tests
may be needed in a relatively short turn-around time and this
may not be possible with genetic or immunohistochemical analy-
sis. Thus, we therefore conduct this study to detect any correlation
between relatively simple histo-morphometric analysis with Azan
and Toluidine blue as compared with immunohistochemistry by
osteocalcin. These may offer a relatively less complex and quicker
method for appropriate diagnosis. Azan is a trichrome stain that
uses three anionic dyes to mark different tissues histologically. It
is an improvement over the traditional Mallory’s method and
stains muscle fibers red and cartilage/bone matrix blue.8 Toluidine
blue is an acidophilic metachromatic dye that selectively stains
acidic tissue components (sulfates, carboxylates, and phosphate
radicals). It has been extensively used as a vital stain for mucosal
lesions but has also found applications in tissue sections to specif-
ically stain certain components owing to its metachromatic
property.9
OF and FD are the FOLs mostly associated with significant cos-
metic and functional disturbances. As the treatment and prognosis
differs for both, it is important to distinguish between these two
lesions.10
2. Methodology
Forty formalin fixed paraffin embedded (FFPE) blocks of FD and
OF cases from the Oral Pathology Department of the UniversityFig. 1. Osteocalcin staining of trabecular bone: [A] negative [B] weak (+) [C] moderate
cells). Osteocalcin score of 0 and + represent OF cases while ++ and +++ represent FD caCollege Hospital, University of Ibadan Nigeria were sectioned and
stained with hematoxylin and eosin for re-evaluation and inclu-
sion. At the Frankfurt Orofacial Regenerative Medicine (FORM)
Lab, Department for Oral, Cranio-Maxillofacial and Facial Plastic
Surgery, Medical Center of Goethe University Frankfurt, Frankfurt
am Main, Germany, sections were prepared for Azan, Toluidine
blue staining and immunohistochemistry to osteocalcin from each
FFPE block.
2.1. For osteocalcin
The sections were de-paraffinized using xylene and hydrated
with descending grades of alcohol. Each tissue was immersed in
heat-induced epitope retrieval 10mMol citrate buffer pH 6.0 (TA-
250-PM1X), diluted 1:100 with distilled water and incubated at
95 C for 20 min. They were cooled in the buffer for 20 min and
then rinsed in PBS for 5 min. Positive and negative controls were
employed. Thermo-Scientific peroxidase blocking reagent was
added to each section for 15 min, and the sections were rinsed in
0.1% TBST for 5 min. The specimen were incubated for 60 min with
1:200 dilutions of Abcam Mouse monoclonal Anti-Osteocalcin
antibody [OC4-30] (ab13418) and then rinsed with TBST, followed
by incubation with pre-diluted (ready-to-use) Ultra-Vision Quanto
Detection System/Horse Radish Peroxidase for 15 min. One ml of
diaminobenzidine substrate with one drop of diaminobenzidine
chromogen was added to cover the slides, followed by incubation
in a humidity chamber for 5 min. The sections were then immersed
in aqueous Meyer’s haematoxylin and rinsed in distilled water for
5 min. The tissue was dehydrated and subsequently rinsed with
xylene. DPX was applied, and a cover slip placed. Brown staining
of calcified structures was considered as positive for osteocalcin.
Cases with weak staining (0 or +) were categorized as OF while
those with strong staining (++ or +++) where categorized as FD.5(++) [D] strong (+++) (inset red arrow pointing out unstained multinucleated giant
ses. All sections are X40 magnification.
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Each tissue was passed through xylene and descending grades
of ethanol then rinsed in distilled water for 3 min and placed in
nuclear fast red solution for 30 min, rinsed twice under running
water and once in distilled water. Section differentiation via 0.1%
aniline alcohol solution was done for 3 min and stopped by place-
ment in acetic alcohol solution. They were placed in 5% aqueous
phosphotungstic acid for 10 min, rinsed in distilled water and
placed for 5 min in 1part Aniline Blue-Orange mixture to 3 parts
distilled water and briefly rinsed again in distilled water. Absolute
alcohol (100% Isopropanol) was then used to dehydrate the sec-
tions through 2 changes for 2 min each. Xylene was finally used
3 times for 3 min each to clear the slides and cover slips placed.2.3. For toluidine blue
The sections were deparaffinized, hydrated to distilled water
and stained with toluidine blue solution for 1–2 min. They were
then washed in 3 changes of distilled water and dehydrated
quickly through 95% and absolute alcohol, cleared in 2 changes
of xylene for 3 min and a coverslip was placed with DPX.Table 1
Toluidine bone staining intensity compared with osteocalcin bone stain.
Osteocalcin
0




Staining intensity index: 0 = negative, + = weak, ++ = moderate, +++ = strong. Osteocalci
Fig. 2. Toluidine blue stain, [A] negative bone staining with FCT staining strong (+++)
respectively [D] bone staining and FCT staining are both moderate (++) X100.Scoring for Azan and Toluidine blue was evaluated based on
intensity and localization of stain. Azan stained the bone periphery
and core differentially in some cases and only the core bone staining
was used, while toluidine blue staining of bone islands and fibrous
connective tissue were used in the final analysis. Intensity was rela-
tively categorized as no staining, weak, moderate, or strong. All
slides were viewed with a Nikon ECLIPSE 80i microscope (Nikon,
Tokyo, Japan) and microphotographs of selected sections were
recorded with a connected digital camera DS-Fi1 together with a
Nikon digital sight control unit (Nikon, Tokyo, Japan).
Each sample was examined and scored by an oral pathologist.
The data were analyzed using version 20 of the SPSS. The level of
agreement of original and revised diagnosis was determined using
kappa statistics. The level of significance was set at P < .05.
The Helsinki Declaration was followed for this investigation.
3. Results
There were 15 cases of FD according to Hematoxylin and Eosin
(H/E) diagnosis, of these only 6 cases (40%) were confirmed to be
FD by osteocalcin. Another 8 cases initially diagnosed as OF were
revised to FD following moderate to strong osteocalcin staining
(Fig. 1). There were 25 cases of OF according to H/E diagnosis, of+ ++ +++ Total
4 5 4 29
4 2 1 8
0 2 0 3
8 9 5 40
n score of 0 and + represent OF cases while ++ and +++ represent FD cases.
X40 [B and C] negative bone staining with FCT staining weakly (+) X40 and X100
Table 2
Toluidine fibrous connective tissue staining intensity compared with osteocalcin bone stain.
Osteocalcin
0 + ++ +++ Total
Toluidine FCT stain 0 3 0 1 0 4
+ 2 2 2 0 6
++ 4 4 6 3 17
+++ 9 2 0 2 13
Total 18 8 9 5 40
Staining intensity index: 0 = negative, + = weak, ++ = moderate, +++ = strong. Osteocalcin score of 0 and + represent OF cases while ++ and +++ represent FD cases. FCT =
fibrous connective tissue.
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cases initially diagnosed as FD were revised to OF following nega-
tive to weak osteocalcin staining. The measure of agreement
between histology diagnosis and immunohistochemical revision
following osteocalcin was 0.081; p = .608.
For the 26 cases diagnosed as OF by weak or negative osteocal-
cin staining, 20 (76.9%) were negative for toluidine blue bone stain-Fig. 3. Azan stain, [A] blue strong (+++) stain [B] yellow moderate (++) stain [C and D] d
taken as blue weak (+). All sections are X40 magnification.
Table 3
Azan bone-core staining intensity compared with osteocalcin bone stain.
Osteocalcin
0






Staining intensity index: 0 = negative, + = weak, ++ = moderate, +++ = strong. Osteocalciing, while out of 14 FD cases 9 (64.2%) were negative (Table1).
However, 11 (42.3%) cases of OF expressed very strong (+++) tolu-
idine blue staining of the intervening fibrous connective tissue
stroma while only 2 (14.2%) cases of FD showed similar staining
(Fig. 2), this difference was statistically significant [p = .001]
(Table2). Azan stained the core of the calcified bone differentially
from the periphery (Fig. 3). For consistency, we used the bone coreifferential bone peripheral and core staining, C was taken as yellow weak (+) and D
+ ++ +++ Total
0 5 1 14
6 2 2 14
1 2 2 8
1 0 0 1
0 0 0 3
8 9 5 40
n score of 0 and + represent OF cases while ++ and +++ represent FD cases.
S.E. Udeabor et al. / Alexandria Journal of Medicine 54 (2018) 693–697 697staining as representative. Weak to strong yellow azan staining of
bone core was seen in 4 (15.3%) cases of OF but this was not seen in
any FD case (Table3).
4. Discussion
The two most confused benign FOLs are FD and OF, and
although clinical, histological and radiographic characterization
may aid with diagnosis,10 further investigations are still needed
for a completely correct final diagnosis. Previously, researchers
considered that OF and FD were either the same lesion or variants
of the same entity,11 but osteocalcin staining by Toyosawa et al. 5
suggested that they were distinct lesions. In Toyosawa’s5 report,
both OF and FD showed similar expression for all immunohisto-
chemical markers used including that for Runx2 (which determi-
nes osteogenic differentiation from mesenchymal stem cells) but
FOLs with moderate to strong expression of osteocalcin showed
mutations of the GNAS-1 gene found in FD. While on the other
hand the FOLs with weak expression or no expression of osteocal-
cin, also had no mutations of the GNAS-1 gene, and were catego-
rized as OF.
We thus validated or revised previous H/E diagnosis of FOLs in
our study based on the expression of osteocalcin, and from the
number of cases that needed re-categorization, it was evident that
the diagnosis of OF and FD still poses a significant challenge for
clinicians and pathologist using only the clinical features and H/E
method for diagnosis. The level of agreement between histology
diagnosis and immunohistochemical diagnosis from our analysis
was very poor indeed and thus we can categorically state that his-
tology criteria is certainly not sufficient to make accurate diagnosis
any longer. However, even though we found that the likelihood of
making a correct diagnosis of OF by H/E was higher than that for
FD, we still suggest that the use of further ancillary tests be incor-
porated as minimum standard in the diagnosis of FOLs.
Oxytalan fibres (so called because they are resistant to acid
hydrolysis), have been reportedly seen in FOLs and they were
found more in OF than FD.12 In our study, Toluidine blue, which
is acidophilic, was found to strongly stain 42.3% of OF and 14.2%
of FD, this difference was statistically significant. Thus, we suggest
that strong Toluidine blue staining of the fibrous connective tissue
stroma of FOLs may most likely indicate an OF. A study by Gulati
et al.,10 using both trichrome and modified Halmi staining in FOLs,
showed more oxytalan fibres in OF by the strong purple coloration
observed compared to FD cases. They also suggested that the use of
such histomorphometric tests might be a solution to the misdiag-
nosis of these two FOLs, as well as a pointer to their origin. From
our study and that by Gulati et al.,10 we advise that in facilities
where genetic analysis or immunohistochemical processing may
be challenging, a minimum of metachromatic or trichrome staining
as suggested above may be useful to help resolve diagnosis of OF
and FD.
Azan as earlier stated is a trichrome stain that uses three anio-
nic dyes to mark different tissues histologically. It is an improve-
ment over the traditional Mallory’s method and stains muscle
fibers red and cartilage/bone matrix blue.8 A study on its use in
ameloblastoma has demonstrated that it could differentiate the
fibrous connective tissue from the stellate reticulum in all the vari-
ants of ameloblastoma stained. This is an improvement over the
routine H and E staining.13However, in the present study, the pattern of Azan peripheral
and core bone staining was inconsistent for both OF and FD and
currently we feel it is not useful to differentiate one lesion from
the other. This is a lesson that not all trichrome staining methods
may be useful for differentiating these lesions and as such further
research is needed to test applicable methods.5. Conclusion
From our experience and other reports noted, the diagnosis of
OF and FD by H/E alone is mostly incorrect and thus should be sup-
ported by relatively simple histomorphometric analysis such as
Toluidine blue staining in the absence of more advanced tech-
niques like immunohistochemistry and genetic analysis.Acknowledgements
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